CytoSorbents Corporation reported third quarter 2025 financial results, announcing revenue of $9.5 million, a 10% increase compared to $8.6 million in the third quarter of 2024. On a constant currency basis, revenue grew by 4%. The company noted record performance in distributor territories and near-record performance in direct sales outside Germany. Gross margin for the quarter was 70%, up from 61% in the same period last year, attributed to the resolution of prior production and manufacturing issues. CytoSorbents also amended its credit agreement with Avenue Capital Group, securing an additional $2.5 million in cash and extending the interest-only period through December 31, 2026, with the potential for further extension and funding contingent on regulatory approval. The company implemented a workforce and cost reduction program aimed at achieving cash-flow breakeven by the first quarter of 2026. Additionally, CytoSorbents submitted a DrugSorb-ATR De Novo pre-submission package to the FDA, with a regulatory decision anticipated by mid-2026.